|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT).
|
21738479 |
2011 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining with TrkA receptor and pan-Trk receptor antibodies revealed a positive staining in pancreatic NETs in 24.2% (8/33) and 33.3% (11/33), respectively.
|
29563190 |
2018 |
|
Von Hippel-Lindau Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, a clinical study was initiated to evaluate the effect of the VEGF tyrosine kinase receptor inhibitor SU5416 in patients with VHL syndrome.
|
10804089 |
2000 |
|
Vertigo
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic.
|
31738426 |
2019 |
|
Venous malformation
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Most VMs are associated with the activating mutation L914F in the endothelial cell (EC) tyrosine kinase receptor TIE2.
|
30626204 |
2019 |
|
Venous malformation
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the endothelial cell (EC) tyrosine kinase receptor TIE2 cause inherited and sporadic forms of venous malformation.
|
23633549 |
2013 |
|
Uric acid measurement (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study.
|
28095793 |
2017 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MTC-miR146b should be regarded as an effective candidate for oral delivery and could improve the efficacy of immunotherapies for ulcerative colitis and colitis-associated cancer.
|
30445446 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The overexpression of members of the ErbB tyrosine kinase receptor family has been associated with cancer progression.
|
16275754 |
2005 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression.
|
15077169 |
2004 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The absence of gp140TRK-A mRNA expression, whether or not the N-myc proto-oncogene is amplified, is associated with tumor progression.
|
8433391 |
1993 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The neurotrophic tyrosine kinase receptor TrkA (NTRK1) and its ligand nerve growth factor (NGF) are emerging promoters of tumor progression.
|
29802376 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
c-Met is a tyrosine kinase receptor largely described to be involved in cancer progression and metastasis.
|
23276936 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RON (recepteur d'origine nantais), a tyrosine kinase receptor for macrophage-stimulating protein (MSP) was implicated in tumor progression.
|
18165235 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
|
15827676 |
2005 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression.
|
15870692 |
2005 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Platelet-derived growth factors alpha (PDGFA) is a tyrosine kinase receptor activator which is known to be amplified in the malignancies, and their expression levels are correlated to tumor progression and reduced overall survival.
|
28342264 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The Erbb-2 (neu in rat and Her-2 in humans) tyrosine kinase receptor is an oncoantigen (i.e., a tumor-associated molecule directly involved in cancer progression).
|
20332241 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression.
|
31011143 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
An autocrine loop involving NTRK1 and NGF is associated with tumor progression in prostate carcinoma and in breast cancer.
|
16242838 |
2006 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
DDR1, a non-integrin collagen tyrosine kinase receptor, is overexpressed in several malignancies and plays a role in cancer progression and metastasis.
|
29486622 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
DDR1, a non-integrin collagen tyrosine kinase receptor, is overexpressed in several malignancies and plays a role in cancer progression and metastasis.We now evaluated whether DDR1 is able to exert a role in breast cancer biology by functionally cross-talking with IR.
|
28591735 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We further identified essential thrombocythemia (ET)-related candidate mutations such as SESN2 and NTRK1, which may be involved in neoplasm progression.
|
22385957 |
2012 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
19651775 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Expression of both hepatocyte growth factor (HGF) and its tyrosine kinase receptor met has been demonstrated in normal tissues and their neoplastic counterparts, implicating these factors in normal development and tumour progression.
|
11748645 |
2002 |